Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-α

Renal Failure

Volumn 34, Issue 4, 2012, Pages 429-434

  Hu, Ching Chih ^a,b   Weng, Cheng Hao ^a,b   Lin, Chih Lang ^a,b   Tien, Hui Ching ^a   Kuo, Yen Lin ^a   Chien, Cheng Hung ^a   Yen, Cho Li ^a   Lin, Chun Yen ^a,b   Chien, Rong Nan ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Anemia; EGFR; HCV; Interferon; Ribavirin

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; FEMALE; GLOMERULUS FILTRATION RATE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT; VIRUS LOAD;

ADMINISTRATION, ORAL; ANEMIA; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEMOGLOBINS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; RNA, VIRAL; TAIWAN;

EID: 84859583276     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.650562     Document Type: Article

References (28)

1. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436-2441. (Pubitemid 46929498)
2. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328(25):1797-1801. (Pubitemid 23174709)
3. Fassio E. Hepatitis C and hepatocellular carcinoma. Ann Hepatol. 2010;9:119-122.
4. Hadigan C, Kottilil S. Hepatitis C virus infection and coinfection with human immunodeficiency virus: Challenges and advancements in management. J Am Med Assoc. 2011;306(3): 294-301.
5. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009;49(4):1335-1374.
6. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4): 529-538. (Pubitemid 44307383)
7. Huang JF, Yu ML, Lee CM, et al. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: A 1386-patient study from Taiwan. Aliment Pharmacol Ther. 2007;25(9):1029-1037.
8. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132(7):517-524. (Pubitemid 30171890)
9. Yu ML, Lin SM, Chuang WL, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: A nationwide, multicentre study in Taiwan. Antivir Ther. 2006;11(8):985-994.
10. Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med. 1998;129(2):94-99. (Pubitemid 28337250)
11. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436(7053):967-972. (Pubitemid 41191673)
12. Kowdley KV. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol. 2005;39(1 Suppl.):S3-S8. (Pubitemid 40024231)
13. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339(21):1485-1492. (Pubitemid 28543496)
14. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339(21): 1493-1499. (Pubitemid 28543497)
15. Akram M, Idrees M, Zafar S, et al. Effects of host and virus related factors on interferon-alpha+ribavirin and pegylatedinterferon+ ribavirin treatment outcomes in chronic Hepatitis C patients. Virol J. 2011;8:234.
16. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-982.
17. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358(9286):958-965. (Pubitemid 32913521)
18. Sulkowski MS, Wasserman R, Brooks L, et al. Changes in hemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat. 2004;11(3):243-250. (Pubitemid 38658449)
19. Takaki S, Tsubota A, Hosaka T, et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol. 2004;39(7):668-673. (Pubitemid 39149355)
20. McHutchison JG, Manns MP, Brown Jr. RS, et al. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol. 2007;102(4):880-889. (Pubitemid 46496635)
21. Jen JF, Glue P, Gupta S, et al. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit. 2000;22(5):555-565.
22. Snoeck E, Wade JR, Duff F, et al. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol. 2006;62(6):699-709. (Pubitemid 44749547)
23. Reau N, Hadziyannis SJ, Messinger D, et al. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008;103(8):1981-1988.
24. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36(5 Suppl. 1):S237-S244. (Pubitemid 35253486)
25. Hadziyannis SJ, Sette H Jr., Morgan TR, et al. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346-355.
26. Abstracts of the Biennial Meeting of the International Association for the Study of the Liver, April 15-16, 2002 and the 37th Annual Meeting of the European Association for the Study of the Liver, April 18-21, 2002. Madrid, Spain. J Hepatol. 2002;36(Suppl. 1):1-298; PubMed 12051238.
27. Bruchfeld A, Lindahl K, Schvarcz R, et al. Dosage of ribavirin in patients with hepatitis C should be based on renal function: A population pharmacokinetic analysis. Ther Drug Monit. 2002;24(6):701-708. (Pubitemid 35379522)
28. Lindahl K, Schvarcz R, Bruchfeld A, et al. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat. 2004;11(1): 84-87. (Pubitemid 38221622)